Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE: Exhaled Particles in Lung Pharmacokinetics
NCT04914273Phase 1Completed
- Sponsor
- Fraunhofer ITEM
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salbutamol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Fraunhofer ITEM. Primary endpoint: Salbutamol concentration assessed in exhaled particles. Started Jun 2021; status: completed.
02
Drugs
salbutamol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04914273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04914273.